Neurocrine Biosciences (NBIX) Panoramica del titolo
Neurocrine Biosciences, Inc. scopre, sviluppa e commercializza farmaci per disturbi neurologici, psichiatrici, endocrini e immunologici negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per NBIX dai nostri controlli di rischio.
NBIX Community Fair Values
Create NarrativeSee what 94 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Neurocrine Biosciences
38.0% sottovalutato sconto intrinseco
Neurocrine Biosciences is set to achieve a 40x future PE ratio with a 17% revenue boost
View narrativeKA
Updated 26 Jul 2025
Concorrenti di Neurocrine Biosciences, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$151.83 |
| Massimo di 52 settimane | US$186.12 |
| Minimo di 52 settimane | US$122.14 |
| Beta | 0.38 |
| Variazione di 1 mese | -1.56% |
| Variazione a 3 mesi | -4.08% |
| Variazione di 1 anno | 4.24% |
| Variazione a 3 anni | 34.23% |
| Variazione a 5 anni | 59.74% |
| Variazione dall'IPO | 1,114.64% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 09
NBIX: Future Pipeline Milestones And Vykat Execution Will Drive Upside
The updated analyst price target framework for Neurocrine Biosciences now points to a fair value of about $174, slightly below the prior $179. Analysts are factoring in survey backed confidence in Crenessity and solid recent earnings, along with a modestly higher discount rate and a slightly lower future P/E assumption.Seeking Alpha • Aug 22
Neurocrine Biosciences: 'House Full Of Options'
Summary Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation. Pipeline optionality is significant but hard to quantify; even with conservative assumptions, current business fundamentals justify a bullish stance. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 19
NBIX: Future Pipeline Execution Will Drive Upside Beyond Current Market Skepticism
The analyst fair value estimate for Neurocrine Biosciences has increased from $170.00 to about $179.47 as analysts incorporate recent price target changes that reflect stronger expectations for Ingrezza and Crenessity, as well as ongoing discussion regarding Vykat and spending related to the Soleno acquisition. Analyst Commentary Recent Street research on Neurocrine Biosciences presents a mixed picture, with many firms lifting price targets after what they describe as strong Q2 results for Ingrezza and Crenessity, while a smaller group of bearish analysts is trimming targets and highlighting execution risks around Vykat and spending tied to the Soleno acquisition.Recent updates
Aggiornamento narrativa • Sep 09
NBIX: Future Pipeline Milestones And Vykat Execution Will Drive Upside
The updated analyst price target framework for Neurocrine Biosciences now points to a fair value of about $174, slightly below the prior $179. Analysts are factoring in survey backed confidence in Crenessity and solid recent earnings, along with a modestly higher discount rate and a slightly lower future P/E assumption.Seeking Alpha • Aug 22
Neurocrine Biosciences: 'House Full Of Options'
Summary Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation. Pipeline optionality is significant but hard to quantify; even with conservative assumptions, current business fundamentals justify a bullish stance. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 19
NBIX: Future Pipeline Execution Will Drive Upside Beyond Current Market Skepticism
The analyst fair value estimate for Neurocrine Biosciences has increased from $170.00 to about $179.47 as analysts incorporate recent price target changes that reflect stronger expectations for Ingrezza and Crenessity, as well as ongoing discussion regarding Vykat and spending related to the Soleno acquisition. Analyst Commentary Recent Street research on Neurocrine Biosciences presents a mixed picture, with many firms lifting price targets after what they describe as strong Q2 results for Ingrezza and Crenessity, while a smaller group of bearish analysts is trimming targets and highlighting execution risks around Vykat and spending tied to the Soleno acquisition.
Aggiornamento narrativa • Aug 05
NBIX: Future Upside Will Rely On Execution Across Core Neuroscience Pipeline
Neurocrine Biosciences' updated analyst price target has increased by about $20 to align with a fair value estimate of roughly $213, as analysts factor in stronger contributions from Ingrezza and Crenessity, the addition of Vykat XR, and recent beat and raise quarterly results, while also using a slightly higher discount rate and more measured assumptions for revenue growth and profit margins alongside a higher future P/E multiple. Analyst Commentary Recent Street research on Neurocrine Biosciences points to a generally constructive tone, with multiple firms lifting price targets after the latest Q2 results and the inclusion of Vykat XR from the Soleno acquisition.Aggiornamento narrativa • Jul 22
NBIX: Pipeline Execution And Sector Momentum Will Shape Fairly Valued Outlook
The analyst fair value estimate for Neurocrine Biosciences has been raised from $151.68 to $170.00, reflecting a series of higher Street price targets tied to updated Q2 expectations, stronger Ingrezza prescription trends, and added contributions from the Vykat XR acquisition as well as broader biotech fund flows. Analyst Commentary Recent Street research on Neurocrine Biosciences centers on how the company balances near term prescription trends with longer term growth drivers such as Vykat XR, Crenessity and the broader development pipeline.Aggiornamento narrativa • Jul 08
NBIX: Sector Dependence And Product Uptake Uncertainty Will Pressure Forward Returns
Analysts have raised the Neurocrine Biosciences price target by about $8 to $151.68, citing updated models that reflect slightly higher projected revenue growth, profit margins, and a modestly higher future P/E multiple, supported by recent positive research commentary on Ingrezza, Crenessity, Vykat XR, and the broader biotech sector. Analyst Commentary Recent research on Neurocrine Biosciences points to generally constructive sentiment, with several firms lifting price targets and highlighting drivers such as Ingrezza expectations, the addition of Vykat XR, and the runway for key endocrine and neurology assets.
Aggiornamento narrativa • Jun 24
NBIX: Future Upside Will Rely On Expanding Rare Disease Franchise
Analysts have nudged their price target for Neurocrine Biosciences higher to $243.06 from $241.76, citing updated views on revenue growth, profit margins, and future P/E expectations following recent coverage initiations and the addition of Soleno Therapeutics' Vykat XR to the portfolio. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a generally constructive tone, with several firms updating views on the stock following the completion of the Soleno Therapeutics acquisition and fresh coverage initiations.Articolo di analisi • Jun 19
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults. See our latest analysis for Neurocrine Biosciences. At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026...Aggiornamento narrativa • Jun 09
NBIX: Future Upside Will Depend On Rare Disease Portfolio Execution
Analysts have lifted the fair value estimate for Neurocrine Biosciences by about $6 to $192.88, reflecting updated views on revenue growth, profitability and valuation after the Soleno acquisition, along with recent Street research highlighting a long runway for key drugs and additional contributions from Vykat XR. Analyst Commentary Recent Street research around Neurocrine Biosciences has been broadly constructive, with several firms updating models after the Soleno acquisition and new readthroughs on key products.Aggiornamento narrativa • May 26
NBIX: Pipeline Execution And Integration Risks Will Shape Balanced Future Returns
Analysts lifted their fair value target for Neurocrine Biosciences by about $3 to $144, citing updated assumptions for revenue growth of 14.83%, a profit margin of 18.43%, and a recalibrated future P/E of 21.28x that reflects confidence in the long runway of its key approved drugs and potential contributions from Crenessity and osavampator. Analyst Commentary Recent Street research on Neurocrine Biosciences highlights a mix of optimism around the company’s approved therapies and emerging pipeline, alongside selective caution on execution and valuation.Articolo di analisi • May 08
Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next
Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...Aggiornamento narrativa • May 07
NBIX: Future Upside Will Depend On Execution Across Two Core Franchises
The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.Aggiornamento narrativa • Apr 21
NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution
The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.Aggiornamento narrativa • Apr 07
NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns
Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.Aggiornamento narrativa • Mar 24
NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress
Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.Aggiornamento narrativa • Mar 09
NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns
Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.Aggiornamento narrativa • Feb 23
NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook
Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.Aggiornamento narrativa • Feb 09
NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery
Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.Aggiornamento narrativa • Jan 24
NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises
Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.Aggiornamento narrativa • Jan 10
NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns
Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.Aggiornamento narrativa • Dec 17
NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns
Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.Aggiornamento narrativa • Dec 03
NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value
Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.Aggiornamento narrativa • Nov 19
NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds
Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.Aggiornamento narrativa • Nov 05
NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value
The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.Aggiornamento narrativa • Oct 22
Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results
Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.Rendimenti per gli azionisti
| NBIX | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -3.0% | -2.1% | -1.1% |
| 1Y | 4.2% | 36.5% | 11.7% |
Ritorno vs Industria: NBIX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 36.5 % nell'ultimo anno.
Rendimento vs Mercato: NBIX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 11.7 % nell'ultimo anno.
Volatilità dei prezzi
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: NBIX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di NBIX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1992 | 2,500 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. scopre, sviluppa e commercializza farmaci per disturbi neurologici, psichiatrici, endocrini e immunologici negli Stati Uniti e a livello internazionale. I prodotti dell'azienda includono INGREZZA per la discinesia tardiva e la corea associate alla malattia di Huntington, Orilissa in compresse per l'endometriosi, Oriahnn in capsule per il trattamento dei fibromi uterini e CRENESSITY per il trattamento dell'iperplasia surrenale congenita, oltre a offrire prodotti con il nome di ALKINDI ed Efmody. I suoi candidati prodotti in fase di sviluppo clinico includono NBI-1076986 per il trattamento dei disturbi del movimento; Osavampator per la risposta inadeguata al trattamento nel disturbo depressivo maggiore; NBI-1117568 per il trattamento della schizofrenia e della mania bipolare; NBI-1117567 per il trattamento della malattia di Alzheimer; NBI 921355 per il trattamento dell'epilessia; NBIP-01435 per il trattamento dell'iperplasia surrenale congenita; NBIP-2118 per il trattamento dell'obesità e delle malattie metaboliche correlate; NBI-1070770 per il trattamento del disturbo depressivo maggiore; NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675 e NBI-1065890 per patologie neuropsichiatriche e neurologiche.
Neurocrine Biosciences, Inc. Riepilogo dei fondamenti
| NBIX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$15.20b |
| Utili (TTM) | US$705.50m |
| Ricavi(TTM) | US$3.37b |
21.9x
Rapporto P/E4.6x
Rapporto P/SNBIX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| NBIX Conto economico (TTM) | |
|---|---|
| Ricavi | US$3.37b |
| Costo del fatturato | US$1.20b |
| Profitto lordo | US$2.18b |
| Altre spese | US$1.47b |
| Utili | US$705.50m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 6.94 |
| Margine lordo | 64.48% |
| Margine di profitto netto | 20.91% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato NBIX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/17 03:22 |
| Prezzo dell'azione a fine giornata | 2026/09/17 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Neurocrine Biosciences, Inc. è coperta da 39 analisti. 24 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Jeffrey Walch | Bernstein |